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Abstract 
Importance: There is a concern that Helicobacter pylori therapy containing-clarithromycin 
might be associated with acute neuropsychiatric events.  
Objective: To examine the association between H. pylori therapy containing-clarithromycin and 
acute neuropsychiatric events. 
Design, setting, and participants: A self-controlled case series study was conducted using the 
Clinical Data Analysis and Reporting System database in Hong Kong to explore any association. 
The exposure of interest was H. pylori therapy containing-clarithromycin in the out-patient 
setting. Study subjects aged ≥18 at cohort entry, must have both exposure to H. pylori therapy 
containing-clarithromycin and their first recorded neuropsychiatric events from January 1, 2003 
to December 31, 2012. A post-hoc nested case-control analysis was also performed on patients 
receiving H. pylori therapy containing-clarithromycin. 
Main outcomes and measures: The primary outcome was composite neuropsychiatric events 
while secondary outcomes were psychotic events and cognitive impairment. Risk periods in the 
self-controlled case series analysis were defined as 14-day pre-exposure period, current use(day 
1-14 since prescription start date) and recent use(day 15-30). Age adjusted incidence rate 
ratios(IRR) were estimated using the conditional Poisson regression.  
Results: Of 66 559 patients who had at least one out-patient prescription of H. pylori therapy 
containing-clarithromycin, 1824 patients had their first recorded composite neuropsychiatric 
events during the study period. An increased IRR of 4.12(35 composite neuropsychiatric events 
during 72 person-years; 95% CI, 2.94-5.76) during current use was observed but not in recent 
use(9 events during 82 person-years; IRR, 0.95; 95% CI, 0.49-1.83) and 14-day pre-exposure 
period(14 events during 72 person years; IRR, 1.63; 95% CI, 0.96-2.77) versus baseline(1766 
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events during 16 665 person-years). Similarly, both the risk of psychotic events and cognitive 
impairment increased during current use versus baseline although this subsequently returned to 
baseline incidence levels during recent use. The crude absolute risk of composite 
neuropsychiatric events, psychotic events and cognitive impairment during current use were 
0.45, 0.12 and 0.12 per 1000 prescriptions respectively. The nested case-control analysis also 
gave similar results to that of the self-controlled case series. 
Conclusions and relevance: This study shows evidence of a short-term increased risk of 
neuropsychiatric events associated with H. pylori therapy containing-clarithromycin. 
No of words in abstract: 345 (max: 350) 
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Introduction 
Clarithromycin is used for the treatment of respiratory infections including community acquired 
pneumonia.1 It is also commonly prescribed in combination with amoxicillin/metronidazole, plus 
proton pump inhibitors (PPIs) as a first-line standard treatment for Helicobacter pylori 
eradication.2 Among potential adverse events associated with the use of clarithromycin, 
neuropsychiatric symptoms were described in 1995 when two patients with acquired immune 
deficiency syndrome developed delusions, anxiety and agitation following treatment with 
clarithromycin for mycobacterium avium complex infection.3 Thereafter, several case reports 
raised concerns that clarithromycin might be associated with neuropsychiatric events in patients 
with or without other long-term comorbidities such as renal disease, hypertension and 
obstructive airway disease.4-16 One literature review reported 38 adult patients with 
clarithromycin-induced neuropsychiatric events also suggesting a possible link between 
clarithromycin and neuropsychiatric events.17 The majority of the reported neuropsychiatric 
symptoms were related to psychotic manifestations and cognitive disturbances.17 In these reports, 
the neuropsychiatric symptoms appeared to be resolved after discontinuation of clarithromycin 
treatment. Notably, clarithromycin was frequently reported to be associated with mania based on 
unpublished reports from the World Health Organization and the Food and Drug 
Administration.18  
Apart from clarithromycin monotherapy, neuropsychiatric symptoms were also observed in 
patients receiving H. pylori therapy containing-clarithromycin.19-25 Despite signal detection 
implicating clarithromycin as the causative agent of neuropsychiatric events, no population-
based study to date has been conducted to assess and evaluate the neuropsychiatric risk 
associated with clarithromycin.  
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Patients receiving clarithromycin might have a higher risk of severe acute infections than those 
prescribed amoxicillin or other penicillins. Due to different underlying neuropsychiatric risks, 
indication bias might result in findings of non-causal associations. In our previous work, we 
examined the association between cardiovascular events and clarithromycin using the cohort of 
H. pylori therapy containing-clarithromycin in a secondary analysis to reduce confounding.26 
Using similar methods, we further explore the safety considerations of clarithromycin in this 
study, by investigating the association between H. pylori therapy containing-clarithromycin and 
acute neuropsychiatric events.  
Method 
Data sources 
The data was retrieved from the Clinical Data Analysis and Reporting System database which is 
developed and managed by the Hospital Authority in Hong Kong.27 The Hospital Authority 
currently manages 42 public hospitals and institutions, 47 Specialist Out-patient Clinics, and 73 
General Out-patient Clinics.28 More than seven million local residents have access to these 
primary, secondary and tertiary public healthcare services through seven hospital clusters.27 In 
the Hospital Authority, the Clinical Management System was established as a clinical 
workstation to provide access to wards and ambulatory settings, as well as laboratory, radiology 
and pharmacy systems in public hospitals and clinics. The clinical information is directly 
recorded into the Clinical Management System by clinicians and other healthcare professionals. 
The health records in the Clinical Management System are then routinely transferred to the 
Clinical Data Analysis and Reporting System for audit and research purposes. Since 1993, the 
electronic health records in the Clinical Data Analysis and Reporting System included patient 
demographics and clinical data such as diagnosis, operation, prescription use, accident & 
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emergency, out-patient and in-patient visits. A unique patient identifier is generated for each 
individual patient to link all medical records. To protect patient confidentiality, all medical 
records are anonymized. This database has been used to conduct high-quality epidemiological 
studies in Hong Kong26,29,30 and multinational pharmacovigilance studies31,32.  
Study design 
The self-controlled case series method is a case-only approach for eliminating between-person 
confounding. It compares the rate of outcomes in risk periods with baseline within individuals, 
derived from cohort methodology.33 The analysis is based on individuals who must have had 
both the exposure and the event. In Hong Kong, H. pylori infection is diagnosed during 
endoscopy by rapid urease test or histology before treatment and empirical therapy is not a 
common practice. In this study, the exposure of interest was H. pylori therapy containing-
clarithromycin in the out-patient setting. We defined it as co-prescription of clarithromycin with 
either amoxicillin or metronidazole, and one of the PPIs with British National Formulary 
recommended doses (eTable 1) as there are no other indications for this co-prescription. The co-
prescriptions must share the same prescription start date with an overlapping duration of 7-14 
days. We estimated the treatment duration by adding one day to the difference of prescription 
end date and prescription start date. The application of a strict definition increases the precision 
of identifying such exposure to avoid introducing bias from identifying other acute infection 
indications. 
The primary outcome was the first recorded acute composite neuropsychiatric events while 
secondary outcomes were the first recorded psychotic events and first recorded cognitive 
impairment as principal diagnosis for an in-patient or accident & emergency admission. All cases 
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were identified according to the 9th International Classification of Diseases (eTable 2 in the 
supplement). Based on the symptoms (i.e. psychosis, delirium, mood and sleep disturbances) 
described in the identified case reports19-25, a list of diagnostic codes which describe acute and 
possibly drug-induced clinical conditions for neuropsychiatric events was developed and 
independently reviewed by two local clinical psychiatrists (EL and WC). To enhance the 
reliability and validity of the case definition, a final list of diagnostic codes was then confirmed 
by consensus in meetings involving psychiatrists and researchers.  
Patients who were aged ≥18 years and received at least one out-patient prescription of H. pylori 
therapy containing-clarithromycin during the study period (from January 1, 2003 to December 
31, 2012) were identified. If there was a preceding gap of more than 7 days with no prescription, 
this was defined as a new prescription. In order to remove those patients with more severe health 
issues identified on the prescription date, patients who received any clarithromycin prescription 
or in-patient therapy prior to the first out-patient therapy were excluded. Follow-up was censored 
if patients received a clarithromycin prescription or in-patient therapy after the first out-patient 
therapy. This cohort of patients with H. pylori therapy containing-clarithromycin was also 
described in our previous publication.26 
The observation period (Figure 1) started one year after patients entered the database and follow-
up was censored at the study end date, death, or any censoring events described above. As 
treatment duration for each prescription ranged from 7-14 days, two risk periods were defined as 
follows: current use (day 1-14 since prescription start date) and recent use (day 15-30). In order 
to correct the estimates if the exposures are event-dependent, we also separated a 14-day pre-
exposure period from the baseline. This could address bias resulting from change in baseline 
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incidence in the period just before the exposure if the event alters the likelihood of subsequent 
exposure.  
Statistical analyses and sensitivity analyses 
Incidence rate ratios (IRRs) with age adjustment in single years were estimated using the 
conditional Poisson regression, comparing the rate of events during risk periods with that during 
baseline. 
As events identified on the first day of prescription might reflect the underlying health status of 
the patient rather than being induced by the therapy of interest, we conducted a sensitivity 
analysis by either removing the first day of prescription from current use of treatment or 
including it in the pre-exposure period (i.e. only consider day 2-14). We carried out additional 
sensitivity analysis to divide current use into two periods (day 1-7 and day 8-14). Another 
sensitivity analysis was conducted to include other ICD-9 codes, which have non-specific 
descriptions for psychotic events to test the robustness of the outcome identification (eTable 2). 
As metronidazole has infrequently been reported to be associated with neuropsychiatric events34-
37, we conducted additional sensitivity analyses that included patients with H. pylori therapy 
containing clarithromycin, amoxicillin and PPIs only. 
We estimated the crude absolute risk with 95% confidence interval for all outcomes as the 
number of events occurred during current use divided by the total number of identified out-
patient H. pylori therapy containing-clarithromycin.30 
A post-hoc nested case-control analysis among patients with out-patient H. pylori therapy 
containing-clarithromycin was conducted to validate the findings of the primary outcome in the 
self-controlled case series analysis. Patients were eligible if they were aged ≥18 at the 
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prescription start date. Follow-up commenced from the date of first out-patient prescription until 
study end date, death, occurrence of event or any censoring events described in the self-
controlled case series analysis. We identified cases within the study period and then randomly 
matched four controls at most to each case by year of birth and sex using the incidence density 
sampling method. We defined current and recent exposure periods similar to the self-controlled 
case series analysis (Figure 1). Only the current exposure period was considered if the 
prescription spanned the current and recent exposure periods. Using conditional logistic 
regression, we estimated the crude and adjusted odds ratios with adjusted variables of psychiatric 
service use in public sector and the use of other drugs (diuretics, calcium channel blockers, 
bronchodilators, psychotropic drugs, antiepileptic drugs, antiparkinsonian drugs, antiretroviral 
drugs, oral corticosteroids and nonsteroidal anti-inflammatory drugs) in the previous 365 days 
prior to the event.  
The statistical analyses were conducted independently by two investigators (AW and CC) for 
quality assurance. All statistical analyses were performed with the use of SAS software, version 
9.3 (SAS Institute) and R version 3.2.0 (www.R-project.org).  
Results 
A total of 1824 patients were identified with a first recorded composite neuropsychiatric event 
(eFigure 1), 354 with a first recorded psychotic event and 726 with a first recorded cognitive 
impairment within the study period (Table 1). The eTable 3 shows the top three most frequently 
reported diagnostic codes for each outcome.   
Table 2 shows the IRRs of all outcomes. Comparing current use with the baseline, the IRR (95% 
CI) for composite neuropsychiatric events was 4.12(2.94-5.76) (35 events during 72 person-
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years) and was reduced to 0.95(0.49-1.83) during recent use (9 events during 82 person-years). 
No increased risk could be found during the pre-exposure period (14 events during 72 person-
years) versus baseline (1766 events during 16 665 person-years). For psychotic events, an 
increased IRR of 5.42(2.77-10.60) was found during current use (9 events during 14 person-
years) but not in other risk periods versus baseline. The risk of cognitive impairment was nearly 
two- to three- fold higher during current use [9 events during 28 person-years; IRR, 2.63(1.36-
5.09)] but there was no evidence of increased risk for all other risk periods. Similar to the 
primary analyses, increased IRRs were also found during day 2-14 since the prescription start 
date for all outcomes versus baseline (eTable 4 and 5). The sensitivity analysis where current use 
was divided into day 1-7 and 8-14 still showed an increased risk for primary outcome and 
psychotic events. For cognitive impairment, an increased risk was observed from day 1 to 14 but 
not for day 1-7. The insignificant finding for the latter period was likely due to unstable 
estimates resulting from small sample size (eTable 6). After including the non-specific ICD-9 
codes in the sensitivity analysis, a similar temporal pattern could also be observed (eTable 7). 
For additional analyses that only considered therapy containing clarithromycin, amoxicillin and 
PPIs, increased risk during current use was still observed for all outcomes (eTable 8). 
A total of 77 758 out-patient H. pylori therapy containing-clarithromycin prescriptions were 
identified during the study period. The crude absolute risk (95% CI) of neuropsychiatric events, 
psychotic events and cognitive impairment during current use of therapy were 0.45(0.32-0.63), 
0.12(0.06-0.22) and 0.12(0.06-0.22) per 1000 prescriptions respectively. 
Similar to self-controlled case series analysis, we found increased crude and adjusted odds ratios 
during treatment in the nested case-control analysis (eTable 9 and 10). 
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Discussion 
Relative to baseline incidence, the incidence of neuropsychiatric events was approximately four-
fold higher during the current use of H. pylori therapy containing-clarithromycin. Notably, the 
risk returned to baseline incidence during recent use of treatment, suggesting that the risk of 
neuropsychiatric events is short-term. In our previous study, we highlighted the cardiovascular 
safety issues of clarithromycin and recommended that clarithromycin should be prescribed with 
caution in patients with high baseline cardiovascular risk.26 In this study, however, given the low 
absolute neuropsychiatric risk, an abrupt change in prescribing practice based on the observed 
increase in neuropsychiatric events is not suggested, particularly in the absence of better 
treatment alternatives. Similar to our previous study26, clinicians should also be well informed of 
transient neuropsychiatric events associated with this treatment. Such transient neuropsychiatric 
events will usually resolve spontaneously after treatment cessation and psychiatric interventions 
can be avoided. 
As the self-controlled case series analysis is suitable for investigating the association between 
transient exposure and acute outcome,33 this method was used in our study to eliminate time-
invariant confounders. However, similar to other observational study designs, it is still 
susceptible to time-varying confounders, such as a short-term change in health status and the use 
of other drugs. To address this, we further adjusted for the use of other drugs in the nested case-
control study analysis and found similar results. 
Notably, acute infection (such as pneumonia) might lead to substantial short-term increased risk 
of neuropsychiatric events.38 As H. pylori is by nature a chronic infection, it is unlikely to 
temporally change the incidence of neuropsychiatric events shortly before and after treatment 
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initiation. Therefore, it is less likely to lead to a spurious short-term association between therapy 
and outcome. Another consideration was that if the neuropsychiatric events were due to the 
infection rather than therapy, we would have observed an increased risk during the pre-exposure 
period. As this was not observed during the pre-exposure period in any of the analyses, we can 
conclude that the short-term increased risk of neuropsychiatric events is more likely to be 
attributable to the therapy than the infection itself. 
Since we investigated H. pylori therapy as the exposure, we could not pinpoint which drug in the 
regimen contributed to the neuropsychiatric events in our study. We hypothesized that 
clarithromycin is the most probable drug as very limited evidence suggested that 
neuropsychiatric events are associated with amoxicillin39,40 or PPIs41-43. We also conducted 
sensitivity analyses to test the robustness of the result when metronidazole (for which there are 
some reports of association with neuropsychiatric events compared with other ingredients)34-37 
was removed from the analysis. The increased risk of neuropsychiatric events during current use 
still remained. In addition, a case report raised an interesting and important case where a patient 
who should have received clarithromycin, lansoprazole, and amoxicillin for H. pylori eradication 
inadvertently took ciprofloxacin instead of clarithromycin for a week due to a dispensing error. 
The neuropsychiatric symptoms did not appear until 2 days after the patient changed back the 
correct regimen (i.e. clarithromycin).25 Moreover, all the identified cases remitted 1-3 days after 
treatment discontinuation in the current literature.19-25 Therefore, clarithromycin is the most 
probable culprit to increase neuropsychiatric risk. Although the potential effect of other drugs in 
the regimen could not be entirely ruled out, the evidence in our study still suggests that H. pylori 
therapy containing-clarithromycin as a whole increases short-term neuropsychiatric risk. This 
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should be brought to the attention of prescribers. Further research is needed to evaluate the 
neuropsychiatric risk associated with different drugs in the regimen.  
Whilst macrolides diffusion to the central nervous system is considered to be poor,44 the 
mechanism pathway governing its neuropsychiatric adverse effect is still unknown. Several 
explanations have been postulated including, direct toxic effects on the central nervous system 
by the active metabolite of clarithromycin (14-hydroxyclarithromycin), alterations in the 
metabolism of cortisol, prostaglandin and other hormones associated with neuropsychiatric 
events, as well as interactions with neurotransmitters (glutamate and gamma-aminobutyric 
acid).17,18 Further research is warranted to explore these hypotheses. 
With reference to the temporal association and dosage, our findings are consistent with the 
results of many potential cases of clarithromycin-induced neuropsychiatric events which were 
summarized in a review.17 This review reported that neuropsychiatric symptoms manifested 1-10 
days after receiving clarithromycin treatment, which is in line with our results. It also appears 
that high dose clarithromycin (more than 1000mg per day for treatment of Mycobacterium avium 
complex or Mvcobacterium abscessus lung infection) is not a necessary condition for 
neuropsychiatric events.3,17,18,45 In our study, patients were prescribed the British National 
Formulary usual recommended dose (1000mg or 500mg per day). 
To our knowledge, this is the first population-based study investigating this association using the 
self-controlled case series method to eliminate any fixed residual confounding. In addition, 
comprehensive linkages between public hospitals and out-patient clinics health services provided 
accurate case ascertainment in our database. Although the retrospective nature of our study 
precludes us from conducting prospective structured interviews to confirm diagnoses, 
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inaccuracies in the ascertainment of cases are minimized as the diagnostic codes for each 
inpatient case in public hospitals in Hong Kong are verified and inputted in a standardized 
format in the computerized clinical management system by the treating clinician. We used 
discharge diagnoses for case identification to ensure that a thorough diagnostic review had been 
performed by the clinical team involving senior specialists and the treating clinician. Previous 
studies using similar methodology to ascertain other clinical outcomes by the Clinical Data 
Analysis and Reporting System have reported high positive predictive values for events such as 
gastrointestinal bleeding29, myocardial infarction26, stroke26, Autism Spectrum Disorders and 
Attention Deficit Hyperactivity Disorder (Man KK, personal communication, 2016). Moreover, 
if we assume the likelihood of diagnostic inaccuracy was the same during the risk period and 
baseline, this error would underestimate the association and increase the likelihood of a negative 
finding. Our study is limited to patients with H. pylori infection, therefore our findings are less 
generalizable to patients who have been prescribed clarithromycin for other indications. Another 
limitation is that we were not able to determine drug adherence due to limited data availability 
and this might lead to some degree of bias from misclassification of exposure. In addition, 
clinical data from private healthcare setting is not available in our database. However, we 
included patients who used public healthcare services at least twice. These included patients 
were very likely to utilize public healthcare services instead of private services, as the public 
healthcare cost is heavily subsidized by the government.  
Conclusion 
This study found a short-term increased risk of neuropsychiatric events associated with current 
use of H. pylori therapy containing-clarithromycin and the temporal increased risk is in full 
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concordance with the treatment duration. Such transient neuropsychiatric events will usually 
resolve spontaneously after treatment cessation and psychiatric interventions can be avoided.  
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Table 1. Demographic information of the identified cohort of patients with Helicobacter pylori 
therapy containing-clarithromycin and final cohort of the included patients. 
Patients with Helicobacter pylori therapy containing-clarithromycin 
N   66 559   
  Mean (years) SD 
Age at cohort entry  50.8 14.8 
Age at first exposure  55.4 14.8 
  N (%) 
Male sex  30 910 (46.4) 
 Composite neuropsychiatric 
events 
 
Psychotic events 
 
Cognitive impairment 
N 1824  354  726 
 Mean (years) SD  Mean (years) SD  Mean (years) SD 
Age at cohort entry 54.4  15.8  55.4 17.3  61.6 14.6 
Age at exposure 59.1 15.6  59.8  16.8  66.2 14.2 
Age at time of event  59.8 16.2  60.9  17.7  67.6 14.8 
 N (%)  N (%)  N (%) 
Male sex 833 (45.7)  170 (48.0)  394 (54.3) 
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Table 2. Results of self-controlled case series analysis for the use of Helicobacter pylori therapy 
containing-clarithromycin and risk of neuropsychiatric events 
 person-years No of events 
Age adjusted incidence rate ratio  
(95% CI) 
Composite neuropsychiatric events 
(n=1824) 
   
 
Baseline 16 665 1766 --- 
14 days before prescription 72 14 1.63 (0.96-2.77) 
Day 1-14 since prescription start date 72 35 4.12 (2.94-5.76) 
Day 15-30 since prescription start date 82 9 0.95 (0.49-1.83) 
Psychotic events (n=354)     
Baseline 3117 340 --- 
14 days before prescription 14 3 1.78 (0.57-5.56) 
Day 1-14 since prescription start date 14 9 5.42 (2.77-10.60) 
Day 15-30 since prescription start date 16 2 1.09 (0.27-4.40) 
Cognitive impairment (n=726)     
Baseline 6583 705 --- 
14 days before prescription 29 6 1.71 (0.76-3.82) 
Day 1-14 since prescription start date 28 9 2.63 (1.36-5.09) 
Day 15-30 since prescription start date 32 6 1.56 (0.70-3.50) 
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Figure 1. Pictorial illustration for self-controlled case series analysis (panel a) and nested case-
control analysis (panel b) 
 
